Sandoz partners with mAbxience on emicizumab biosimilar
Sandoz (SDZ.SW, SDZNY) announced a collaboration with mAbxience for a proposed emicizumab biosimilar; financial terms were not disclosed.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Sandoz partners with mAbxience to develop emicizumab biosimilar###
Sandoz signed a licensing, development, manufacturing, commercialisation deal with mAbxience for a proposed emicizumab biosimilar. Agreement gives Sandoz exclusive global commercialisation rights, excluding Argentina, Uruguay, Paraguay; mAbxience will handle development, manufacturing. Targets Hemlibra reference market